替吉奥或卡培他滨联合奥沙利铂治疗进展期胃癌的临床对比

Clinical comparison of S-1 or capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer

目的:比较替吉奥或卡培他滨联合奥沙利铂治疗进展期胃癌的近期疗效、生活质量和不良反应。方法:对收治的62例进展期胃癌患者进行回顾性分析,其中32例使用替吉奥联合奥沙利铂方案(A组,替吉奥40~60 mg/次,口服2次/d,第1~14天;奥沙利铂130 mg/m^2,静脉滴注2 h,第1天),30例使用卡培他滨联合奥沙利铂方案(B组,卡培他滨每次1 000 mg/m^2,口服2次/d,第1~14天;奥沙利铂130 mg/m^2,静脉滴注2 h,第1天),21 d为1个周期,完成2个周期后评价疗效、生活质量和不良反应。结果:A组和B组的总有效率分别为43.75%和46.67%,A组和B组的疾病控制率分别为56.25%和63.33%,A组和B组的生活质量改善率分别为50.00%和56.67%,A组和B组随访1年的生存率分别为71.88%和80.00%,A组和B组随访2年的生存率分别为56.25%和60.00%,差异均无统计学意义(P>0.05)。B组手足综合征发生率(43.33%)高于A组(15.63%),差异有统计学意义(P<0.05)。结论:替吉奥或卡培他滨联合奥沙利铂治疗进展期胃癌疗效相近,不良反应均可耐受,值得临床推广。

Objective To compare the short-term effects、quality of life and adverse reactions of A scheme or B scheme in the treatment of advanced gastric cancer. Method The data of 62 cases with advanced gastric cancer were studied retrospectively. 32 cases were treated with S-1 combined with oxaliplatin（ A group,oral administration of 40 ～ 60 mg S-1 twice a day for 14 days;intravenous injection of 130 mg / m2 oxaliplatin for 2 hours,in 1 st day,21 days for 1 cycles）;30 cases were given capecitabine combined with oxaliplatin（ B group,oral administration of 1 000 mg / m2 capecitabine twice a day for 14 days;intravenous injection of 130 mg /m2 oxaliplatin for 2 hours,in 1 st day,21 days for 1 cycles）. The efficacy、quality of life and adverse reactions were evaluated after2 cycles. Results The effective rates and disease control rates in A group and B group were 43. 75% 46. 67% and 56. 25% 63. 33%,respectively. The improvement rates of life quality in A group and B group were 50. 00% 56. 67%,respectively. The survival rates of 1,2 years in A group and B group were 71. 88% 80. 00% and 56. 25% 60. 00%,respectively. There was no statistical difference in the above results（ P〉0. 05）. The incidence rate of hand-foot syndrome in B group was obviously higher than that in A group（43. 33% 15. 63%）,the difference was statistically significant（ P〈0. 05）. Conclusion S-1 or capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer is similar efficacy and less adverse reactions,which is worthy of clinical promotion.